![SOLVED: Select any of the trials 2-11. Make measurements of the motion of the blowdart before the collision. Use the information in the video to predict the velocity of the blowdart and SOLVED: Select any of the trials 2-11. Make measurements of the motion of the blowdart before the collision. Use the information in the video to predict the velocity of the blowdart and](https://cdn.numerade.com/ask_images/5b4a5d1c7b6d46c1953f7a7f40c9c0c5.jpg)
SOLVED: Select any of the trials 2-11. Make measurements of the motion of the blowdart before the collision. Use the information in the video to predict the velocity of the blowdart and
![Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials | Signal Transduction and Targeted Therapy Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsigtrans.2017.54/MediaObjects/41392_2017_Article_BFsigtrans201754_Fig1_HTML.jpg)
Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials | Signal Transduction and Targeted Therapy
![PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial | Nature Medicine PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01726-1/MediaObjects/41591_2022_1726_Fig1_HTML.png)